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An examination of the influence of vasoactive drugs on blood flow and
localisation of a monoclonal antibody in human tumour xenografts
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Cancer Research Campaign Laboratories, University ofNottingham, Nottingham NG7 2RD, UK.
It has been suggested that altering the blood flow in tumours
might significantly alter the effectiveness of chemotherapy,
radiotherapy and thermotherapy and also of targeted therapy
with such vectors as monoclonal antibodies (Zanelli &
Fowler, 1974; Bomber et al., 1986; Smyth et al., 1987; Chan
et al., 1984).
Bomber et al. (1986) showed that the beta-adrenoreceptor
blocker propranolol increased tumour perfusion rates in a
transplanted mouse sarcoma by two to three fold. This was
thought to be due to the drug acting on the heart, reducing
cardiac output and blood pressure, which in turn resulted in
a compensatory sympathetic vasoconstriction in an attempt
to maintain blood pressure. Tumour blood vessels lack
smooth muscle (Chan et al., 1984), and do not respond to the
compensatory vasoconstriction. The net consequence was a
change in the relative perfusion rates, with an increase in
tumour blood flow, although these authors did not report
whether there was a change in blood flow rates in other
organs. Smyth et al. (1987) used the beta blockers propra-
nolol and pindolol in an attempt to increase localisation
of a monoclonal antibody in a transplanted mouse thymoma.
Although there was an increase in localisation, there was also
up to 50% reduction in blood levels of the antibody. Thus,
although there was a good increase in tumour to blood
ratios, this was due in large part to the reduced blood
survival of the antibody. The reason for this reduction in
blood survival was unclear, and there was in fact a reduced
level of antibody in all tissues examined (except the tumour),
although the whole body retention of the antibody was not
reported.
The present study was carried out in nude mice with
human tumour xenografts to examine the influence of pro-
pranolol and pindolol on tumour blood flow rates, and on
the extent of tumour localisation and whole body catabolism
of an anti-tumour monoclonal antibody (791T/36) and an
isotype matched IgG2b.
Nude mice (Harlan Olac, Oxon, UK) were used through-
out. They were housed in isolator cabinets (ACE Isolator
Systems Ltd, Powys, UK) with sterile bedding, food and
water. Human tumour lines used were the colon carcinomas
Colo-205 and HCT8 and the osteosarcoma 791T. All were
routinely passaged by aseptic subcutaneous implantation into
the flank of the mice of pieces of tissue about 3 mm3. The
tumours used in the present studies were 22-27 days old.
Relative blood flow rates, as a proportion of the cardiac
output, in tumour and other organs were determined by the
method of Sapirstein (1958), by the intravenous injection of
5tCi of 86Rb (rubidium chloride, Amersham International,
Bucks., UK) with dissection after 2 min (see Sapirstein (1958)
and Zanelli and Fowler (1974) for accounts of the principle
of the technique). 86Rb count rates were determined on
weighed tumour, organs and blood samples using a LKB
Wallac 80000 gamma counter. To avoid high energy P-par-
ticle counts, counting was with a 400 keV window centred on
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the 1.08 MeV gamma photopeak with samples in thick wall-
ed glass tubes.
To determine their effects on blood flow, propranolol and
pindolol (Sigma Chemical Co Ltd, Dorset, UK) were injected
intravenously 15 min before the 86Rb at 10 mg kg-', these
doses and time of injection relative to the 86Rb being based
on those used by Bomber et al. (1986) and Smyth et al.
(1987). Propranolol (as hydrochloride) was dissolved in saline
BP, and pindolol in 0.1% w/v tartaric acid in saline BP.
Although both propranolol and pindolol could alter blood
flow in organs, with some increase in tumour blood flow, the
effects were small and not consistently to the level of statis-
tical significance. In the first test (Table I), propranolol statis-
tically significantly increased the fractional distribution of
86Rb into 791T tumours from 0.75% of cardiac output g-1 to
1.20%, but also significantly increased spleen, kidney and
lung blood flow rates. Although pindolol gave an increase in
tumour blood flow rate (to 0.92% g-') this was not statis-
tically significant, but there was no effect on blood flow in
any organ. In a repeat test (test 2) in mice with the same
tumour, propranolol did increase tumour blood flow, but not
to the level of statistical significance. Pindolol had an even
weaker effect but it did reduce renal blood flow. In mice with
HCT8 xenografts, both propranolol and pindolol statistically
increased tumour blood flow from a mean of 0.32% g-' to
0.89% and 0.69% respectively, and propranolol, but not
pindolol, significantly increased spleen, liver, kidney and lung
blood flow (test 4, Table I). (There was also a significant
increase in the small amount of 86Rb surviving in the blood
in propranolol treated mice). In mice with colon carcinoma
Colo-205, propranolol had no effect on tumour blood flow
(test 5, Table I). Thus, overall, propranolol increased tumour
blood flow in 3/4 tests, but to a statistically significant level
in only two Pindolol had some effect in 3/3 tests, but
statistically significantly in only one. Only propranolol had
widespread effects on 86Rb levels in other tissues, there being
an effect in blood in 2/4 tests, spleen in 2/4, kidney in 2/4,
liver in 1/4 and lung in 3/4.
To determine the effect of the drugs on biodistribution and
tumour localisation of monoclonal antibody 791T/36, mice
with xenografts of osteosarcoma 791T were injected intra-
peritoneally with a mixture of 5 g of '3'I labelled 791T/36
monoclonal antibody mixed with 5 .g 1251I labelled normal
IgG2b (isolated from normal mouse serum). The prepara-
tions had been labelled to a specific activity of approximately
1 mCi mg-' by an lodogen method (Pimm et al., 1982).
Some mice were then given 10mgkg-' of propranolol or
pindolol intraperitoneally 0.5, 19, 25, 42 and 50 hours later.
They were killed at 72 hours and the count rates of the two
radioiodines determined on weighed samples of tissue in
relation to a sample of injected material. This schedule of
repeated injection of the drugs was given based on the obser-
vation of Bomber et al. (1986) that the effects of the drugs on
tumour blood flow were transient, lasting no more than 30
minutes, while the localisation of antibody into tumour is a
slower process, taking two to three days to achieve good
discrimination between tumour and normal tissues (Pimm et
al., 1982).
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Table I Fractional distribution of 86Rb in mice with human tumour xenografts
Mean per cent ofdose (±s.e.) of'Rb per g tissue
Test Tumour Drug Number Mean wt
number type treatmenta ofmice tumour (g) Tumour Blood Spleen Kidney Liver Lung Muscle
791T None 6 0.90 0.75 0.84 4.05 27.68 3.23 7.67 2.20
± 0.05 ± 0.13 ± 0.33 ± 1.80 +0.34 ±0.92 ±0.21
Propranolol 8 1.25 1.20 1.07 6.38 42.00 3.53. 12.74 2.26
± 0.15 ± 0.09 ± 0.70 ± 4.73 ± 0.48 ± 1.35 ± 0.24
pI <0.05 n.s. <0.05 <0.05 n.s. <0.05 n.s.
Pindolol 3 0.92 0.92 0.65 4.91 31.23 3.59 6.69 2.10
±0.16 ±0.08 ±0.25 ±0.94 ±0.11 ±0.43 ±0.18
P n.s. n.s. n.s. n.s. n.s. n.s. n.s.
2 None 5 1.47 0.75 0.39 2.51 17.78 2.27 4.44 1.84
±0.02 ±0.03 ±0.33 ± 1.41 ±0.25 ±0.45 ±0.16
Propranolol 5 1.51 1.03 0.50 3.06 20.29 1.99 6.31 1.41
±0.14 ±0.06 ±0.16 ±2.56 ±0.22 ±0.92 ±0.22
P n.s. n.s. n.s. n.s. n.s. n.s. n.s.
3 None 5 2.16 0.67 0.53 3.60 26.64 2.96 6.29 2.13
±0.06 ±0.03 ±0.40 ± 1.94 ±0.12 ±0.24 ±0.10
Pindolol 5 1.87 0.84 0.59 4.28 17.84 2.72 7.09 1.66
±0.09 ±0.08 ±0.39 ± 1.37 ±0.4 ±0.97 ±0.02
P n.s. n.s. n.s. <0.02 n.s. n.s. <0.01
4 HCT8 None 6 1.08 0.32 0.65 3.19 23.51 3.08 6.13 1.99
±0.04 ±0.06 ±0.36 ±2.10 ±0.21 ±0.49 ±0.22
Propranolol 8 1.89 0.89 1.02 5.44 44.45 4.39 10.3 2.26
±0.15 ±0.08 ±0.59 ±2.55 ±0.31 ±0.46 ±0.14
P <0.02 <0.01 <0.02 <0.001 <0.01 <0.001 n.s.
Pindolol 4 0.62 0.69 0.73 5.61 27.54 3.48 6.57 1.89
± 0.09 ±0.06 ± 1.12 i 1.70 ±0.42 ±0.65 ±0.06
P <0.01 n.s. n.s. n.s. n.s. n.s. n.s.
5 Colo-205 None 5 1.12 0.81 0.44 2.49 17.87 2.13 4.72 1.89
± 0.09 ±0.03 ±0.43 ± 1.35 ±0.28 ±0.27 ±0.26
Propranolol 5 1.43 0.74 0.58 2.93 23.01 3.34 7.37 1.43
± 0.13 ±0.02 ±0.51 ±2.98 ± 1.02 ±0.56 ±0.15
P n.s. <0.02 n.s. n.s. n.s. <0.01 n.s.
ajo mg kg-' i.v. 15 min before injection of86Rb. bFrom Student's t test. n.s. = not significant (P> 0.05).
The '"'I labelled antibody showed localisation in tumour,
in keeping with previous findings in this antibody tumour
xenograft system (Pimm et al., 1982), with a mean of 10% of
the dose g-' of tumour compared with 4.6% for blood and
much lower values for all normal tissues (Table II). In pro-
pranolol treated mice there were no significant alterations in
blood, tumour or other organ levels of the antibody. The
same was found in pindolol treated mice, although here there
was about a four fold increase in the level of radiolabel in the
intestine (stomach and small and large intestine were counted
together). As expected 1251 labelled control IgG2b showed no
tumour localisation. Again neither propranolol nor pindolol
had any significant effect on the biodistribution of the
immunoglobulin, except that pindolol produced a significant
increase in radiolabel levels in the intestine.
In this biodistribution experiment, the whole body reten-
tion of the two radiolabels (taken as a measure of the rates
of catabolism of the immunoglobulins) were not significantly
affected by propranolol treatment. Thus there was
39.1 ± 3.3% survival of '25I from control IgG2b in untreated
mice and 39.3 ± 4.7% in propranolol treated. The values for
"'I from the antibody were 33.2 ± 3.3% in controls and
31.8 ± 4.8% in propranol treated. However, the values in
pindolol treated mice were significantly higher at 49.7 ± 3.7%
for the 1251I of control IgG2b and 45.8 ± 4.1% for 3'I of the
antibody (P<0.05, Student's t test for both radiolabels).
This difference could be accounted for only partly by the
greater retention of the radiolabels in the intestine, with an
average greater level in the whole intestine of 3.9% for the
'"'I labelled antibody and 4.6% for 1251I labelled IgG2b com-
pared to the levels in control animals. The carcass, after
removal of organs, contained the majority of the extra
retained radiolabels. Thus there was on average a 4.4%
greater retention for the '"'I and 5.0% for 1251.
In an additional smaller study, mice with 791T xenografts
were injected with '31I labelled 791T/36 antibody and were
given injections on the day of antibody injection and on the
two subsequent days of 10mg kg-' of propranolol and then
killed for dissection on the third day. Drug treated mice
showed no difference in the biodistribution of the antibody
compared with untreated control mice, tumour levels of the
radioiodine being 2.08% of dose g-' in control mice and
2.16% g-' in drug treated.
The purpose of this study was to examine the feasibility of
using beta-blocking drugs to enhance tumour localisation of
monoclonal antibodies, either for tumour imaging or
targeting of cytotoxic agents. Propranolol, and to a lesser
extent pindolol, did influence tumour blood flow in mice with
human tumour xenografts, although the effect was somewhat
inconsistent, and blood flow in other organs could also be
affected. At its best the effect of propranolol on tumour
blood flow was similar to that described initially by Bomber
et al. (1986) in a mouse sarcoma, with a two to three fold
increase. Although Smyth et al. (1988) achieved enhanced
tumour discrimination by monoclonal antibody in mice with
a syngeneically transplanted tumour by treatment with these
drugs, such an effect was not seen in the present human
tumour xenograft system. In Smyth's system there was a
reduction in the levels of antibody in all normal tissues,
including the blood, and although there was an absolute
increase in tumour levels, the improved tumour discrimina-
tion was due partly to this decline in normal tissue levels.
In the present work, there was no difference in tumour,
blood, organ or whole body levels of antibody or of control
immunoglobulin in propranolol treated mice, and thus this
treatment did not increase tumour discrimination in either a
relative or absolute sense. The same was found with pindolol,
although here there was a significant increase in whole body
survival of the radioiodine from both monoclonal antibody
and control immunoglobulin. This was due particularly to
increased levels in intestine and in the eviscerated carcass. Its
cause is unknown, and perhaps warrants further investiga-
tion, since such an effect could perhaps alter the image
characteristics of radiolabelled antibody given for tumourVASOACTIVE DRUGS AND ANTIBODY TARGETING 71
Table II Effect of propranolol and pindolol on biodistribution of 791T/36 and control IgG2b in nude mice with
osteosarcoma 791T xenografts
Mean per cent ofdose ( s.e.)c ofradiolabelper gram of
Radiolabelled Drug
materiaP treatmentb Blood Tumour Spleen Intestine Kidney Liver Heart Lung Carcass
'311-791T/36 None 4.62 10.02 2.00 0.39 1.27 1.21 2.37 1.92 0.73
± 1.40 ± 1.53 ±0.34 +0.09 +0.28 ±0.32 ±0.64 +0.45 ±0.17
Propranolol 3.23 8.29 1.87 0.33 1.31 1.04 2.18 2.08 0.68
+ 1.35 ± 1.41 ±0.38 ±0.10 ±0.38 +0.32 ±0.64 +0.59 ±0.23
pd n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s.
Pindolol 3.12 9.96 2.26 1.66 1.68 1.48 2.01 2.60 0.94
±0.66 ± 1.25 ±0.27 +0.19 +0.22 ±0.24 +0.34 ±0.31 ±0.16
P n.s. n.s. n.s. <0.001 n.s. n.s. n.s. n.s. n.s.
'25I-IgG2b None 7.35 3.69 2.20 0.65 1.82 2.02 2.06 2.78 1.36
+ 1.03 +0.53 ±0.34 ±0.07 ±0.22 ±0.27 ±0.23 ±0.39 ±0.16
Propranolol 7.14 3.20 2.13 0.61 1.86 1.83 2.26 2.61 1.39
+ 1.13 ±0.41 ±0.30 +0.10 ±0.25 +0.23 ±0.28 ±0.36 +0.20
P n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s.
Pindolol 6.19 3.56 2.93 2.15 2.15 1.99 2.14 3.19 1.77
±0.54 ±0.3 ±0.23 ±0.25 ±0.19 ±0.21 ±0.21 ±0.29 ±0.14
P n.s. n.s. n.s. <0.001 n.s. n.s. n.s. n.s. n.s.
aThe antibody and control IgG2b were injected simultaneously. bI0 mgkg-' injected five times. cSix mice in each group.
Dissected 72 h after injection of radiolabelled materials. Mean tumour weights were controls 1.62±0.31 g; propranolol
treated 2.19±0.43 g; pindolol treated 2.11 ±0.83 g, with no statistically significant differences between either ofthe groups.
dFrom Student's t test. n.s. = not significant (P> 0.05).
imaging and the systemic toxicity of immunoconjugates given
for therapy.
In conclusion these studies suggest that beta blockers may
not give highly effective or consistent increases in tumour
blood flow and therefore may not be very effective in enhanc-
ing tumour localisation of monoclonal antibodies for tumour
imaging or drug targeting. These findings do not preclude the
examination of other drugs capable of altering tumour blood
flow, including other vasoactive drugs (Zeissman et al., 1985;
Burton & Gray, 1987; Smyth et al., 1988). However, the
present findings emphasise that if the intention is to enhance
tumour localisation of monoclonal antibodies or other agents
then due consideration must be given not only to tumour
blood flow rates but also to the relative and absolute levels of
the targeting vector in tumour and in other organs, and to
whether there is any change in the overall catabolism of the
vector.
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